Menu
Search
|

Menu

Close
X

AstraZeneca PLC AZN.L (London Stock Exchange)

5,201.00 GBp
-28.00 (-0.54%)
As of 4:44 PM BST
chart
Previous Close 5,229.00
Open 5,224.00
Volume 1,297,914
3m Avg Volume 1,981,255
Today’s High 5,276.00
Today’s Low 5,190.00
52 Week High 5,585.07
52 Week Low 4,260.00
Shares Outstanding (mil) 1,265.91
Market Capitalization (mil) 65,514.78
Forward P/E 22.12
Dividend (Yield %) 68.90 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.16 Mean rating from 31 analysts

KEY STATS

Revenue (mm, USD)
FY18
5,178
FY17
22,465
FY16
23,002
FY15
24,708
EPS (USD)
FY18
0.268
FY17
2.390
FY16
2.764
FY15
2.233
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
22.12
32.74
Price to Sales (TTM)
vs sector
3.94
5.71
Price to Book (MRQ)
vs sector
6.27
5.37
Price to Cash Flow (TTM)
vs sector
13.70
23.32
Total Debt to Equity (MRQ)
vs sector
144.47
16.46
LT Debt to Equity (MRQ)
vs sector
122.99
12.19
Return on Investment (TTM)
vs sector
7.86
14.38
Return on Equity (TTM)
vs sector
28.47
16.08

EXECUTIVE LEADERSHIP

Leif Johansson
Independent Non-Executive Chairman of the Board, Since 2012
Salary: --
Bonus: --
Pascal Soriot
Executive Director and Chief Executive Officer, Since 2012
Salary: £1,220,000.00
Bonus: £1,916,000.00
Marc Dunoyer
Executive Director, Chief Financial Officer, Since 2013
Salary: £725,000.00
Bonus: £1,025,000.00
Katarina Ageborg
Executive Vice-President Sustainability and Chief Compliance Officer, Since 2011
Salary: --
Bonus: --
Fiona Cicconi
Executive Vice-President, Human Resources, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1 Francis Crick Avenue
Cambridge Biomedical Campus
CAMBRIDGE     CB2 0AA

Phone: +4420.73045000

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

SPONSORED STORIES